Micardis, Pritor(telmisartan)
/ Telmisartan, Actelsar, Kinzalkomb, Kinzalmono, Micardis, Pritor, PritorPlus, Telmisartan, Tolucombi, Tolura, Twynsta (telmisartan) is a small molecule pharmaceutical. Telmisartan was first approved as Micardis on 1998-11-10. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. It has been approved in Europe to treat essential hypertension and hypertension. The pharmaceutical is active against type-1 angiotensin II receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Micardis, Telmisartan (discontinued: Telmisartan)
CombinationsMicardis, Telmisartan amlodipine, Telmisartan hydrochlorothiazide (discontinued: Telmisartan amlodipine, Telmisartan hydrochlorothiazide, Twynsta)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydrochlorothiazide
+
Telmisartan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MICARDIS HCT | Boehringer Ingelheim | N-021162 RX | 2000-11-17 | 3 products, RLD |
Telmisartan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MICARDIS | Boehringer Ingelheim | N-020850 RX | 1998-11-10 | 3 products, RLD, RS |
Amlodipine besylate
+
Telmisartan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TWYNSTA | Boehringer Ingelheim | N-022401 DISCN | 2009-10-16 | 4 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| micardis | New Drug Application | 2023-05-30 |
| micardis hct | New Drug Application | 2023-06-29 |
| telmisartan | ANDA | 2025-01-15 |
| telmisartan and amlodipine | ANDA | 2023-12-15 |
| telmisartan and hydrochlorothiazide | ANDA | 2024-06-20 |
| truemed group llc | Export only | 2022-08-11 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA07: Telmisartan
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA07: Telmisartan and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DB04: Telmisartan and amlodipine
HCPCS
No data
Clinical
Clinical Trials
338 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 4 | 40 | 24 | 45 | 114 |
| Healthy volunteers/patients | — | — | — | 37 | — | — | 1 | — | 38 |
| Essential hypertension | D000075222 | — | I10 | — | 1 | 5 | 1 | 4 | 11 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 3 | 3 | — | 6 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | 1 | 2 | 3 |
| Isolated systolic hypertension | D000092244 | — | — | — | — | 1 | 1 | 1 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | 2 | — | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 1 | 2 | — | 3 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 1 | 1 | 1 | 3 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | 3 | — | 3 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systolic murmurs | D054160 | — | R01.1 | — | — | 1 | — | 1 | 2 |
| Polycystic kidney diseases | D007690 | HP_0000113 | Q61.3 | — | — | 2 | — | — | 2 |
| Dyslipidemias | D050171 | HP_0003119 | — | — | — | 1 | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | — | 1 | — | — | 1 |
| Disease progression | D018450 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | 1 | 2 |
| Insulin resistance | D007333 | HP_0000855 | — | — | 1 | — | — | — | 1 |
| Overweight | D050177 | — | E66.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Telmisartan |
| INN | telmisartan |
| Description | Telmisartan is a member of the class of benzimidazoles used widely in the treatment of hypertension. It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, a xenobiotic and an environmental contaminant. It is a member of biphenyls, a member of benzimidazoles and a carboxybiphenyl. |
| Classification | Small molecule |
| Drug class | angiotensin II receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 144701-48-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1017 |
| ChEBI ID | 9434 |
| PubChem CID | 65999 |
| DrugBank | DB00966 |
| UNII ID | U5SYW473RQ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PPARG
PPARG
Organism
Homo sapiens
Gene name
PPARG
Gene synonyms
NR1C3
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor gamma
Protein synonyms
Nuclear receptor subfamily 1 group C member 3, peroxisome proliferator-activated receptor-gamma 5, peroxisome proliferator-activated receptor-gamma splicing, PPAR-gamma
Uniprot ID
Mouse ortholog
Pparg (19016)
peroxisome proliferator-activated receptor gamma (P37238)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Telmisartan
+
Amlodipine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Telmisartan
+
Hydrochlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Telmisartan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,375 documents
View more details
Safety
Black-box Warning
Black-box warning for: Micardis, Micardis hct, Telmisartan, Telmisartan and amlodipine, Telmisartan and hydrochlorothiazide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,552 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use